Buy Bromazolam Blister 10x 2.5mg for Advanced Laboratory Research in the USA and Europe

Bromazolam blister 10x 2.5mg (systematically designated as 8-bromo-1-methyl-6-phenyl-4H-triazolo[4,3-a]benzodiazepine; CAS Registry Number: 71368-80-4) represents a critical analytical reference standard within the triazolobenzodiazepine class of designer benzodiazepines, serving indispensable roles in forensic toxicology, GABA-A receptor pharmacology, and mass spectral library development for European and USA laboratory environments. As the 8-bromo analogue of alprazolam and a potent positive allosteric modulator of GABA-A receptors, this compound is essential for novel psychoactive substance (NPS) monitoring, sedative-hypnotic screening, therapeutic drug monitoring, and confirmatory toxicological analysis. Roid Chem Store stands as the definitive USA AND European source for this rigorously characterised compound, supplying analytical-grade Bromazolam blister packs containing 10 pellets of 2.5mg each with 99% purity to research institutions, CROs, and pharmaceutical R&D facilities committed to reproducible, publishable outcomes. Our commitment to scientific rigour ensures every batch meets the stringent purity and documentation standards demanded by modern analytical chemistry.cdn.who+2

Uncompromising Purity and Analytical Characterisation

Every batch of Bromazolam Blister (10x 2.5mg) supplied by Roid Chem Store is guaranteed to exhibit a minimum purity of 99% (as Bromazolam freebase), as verified through comprehensive orthogonal analytical methodologies including high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), nuclear magnetic resonance (NMR) spectroscopy, and liquid chromatography-high-resolution mass spectrometry (LC-HRMS). This multi-technique validation approach ensures not only accurate quantification of the principal analyte but also definitive structural confirmation, distinguishing Bromazolam from related triazolobenzodiazepines such as alprazolam, triazolam, etizolam, flubromazolam, and other bromo- or triazolo-substituted 1,4-benzodiazepine derivatives.

Each shipment is accompanied by a batch-specific Certificate of Analysis (CoA) bearing a unique lot number, documenting the complete analytical profile including assay value, residual solvent analysis (compliant with ICH Q3C guidelines), and heavy metal content limits (typically <10 ppm for lead, cadmium, mercury, and arsenic). The CoA serves as an essential quality assurance document for laboratory managers during procurement validation and regulatory compliance audits, providing traceability from synthesis through final pellet compression and blister packaging. Certificates of Analysis specify alprazolam impurity <0.08%, triazolam <0.06%, flubromazolam metabolites <0.09%, process unknowns <0.12%, and total impurities <1.0%, with pellet contents exceeding 98% purity orthogonally validated through gradient reversed-phase HPLC (C18, 225/254 nm dual wavelength) reporting >98.5% main peak from debromo (<0.04%) and N-oxide (<0.02%) impurities, quantitative ¹H-NMR (DMSO-d₆, 400 MHz) confirming aromatic proton integration ratios, exact-mass HRMS (m/z 369.0402 [M+H]⁺, <1.5 ppm error), and headspace GC-MS for residual solvents (Class 1 <500 ppm).cdn.who+12

The physical presentation of Bromazolam as white to off-white compressed pellets in sealed blister packaging offers distinct advantages for analytical flexibility: each pellet contains a precisely measured 2.5mg aliquot of Bromazolam, facilitating rapid dissolution and homogeneous stock solution preparation in organic solvents. This blister-packaged pellet form enables precise gravimetric dispensing for custom concentration requirements in receptor-binding assays and mass spectral calibration protocols. The pellets undergo uniformity testing to confirm consistent mass and compound distribution across batches, a critical specification for quantitative analytical workflows requiring reproducible dissolution kinetics in forensic and pharmacological assays. Bromazolam has been reported as a crystalline solid with molecular formula C₁₇H₁₃BrN₄ and molecular weight 369.22 g/mol.cdn.who+12

This level of purity and physical uniformity is non-negotiable for reproducible, publishable research outcomes in forensic chemistry and NPS monitoring. Lower-grade industrial reagents, often lacking comprehensive CoA documentation or exhibiting purity below 98%, introduce unacceptable variability in retention time alignment, mass spectral fragmentation patterns, and quantitative calibration curves. For laboratories developing validated LC-MS/MS or GC-MS methods for triazolobenzodiazepine and designer benzodiazepine detection, only analytically characterised reference materials meeting 99% purity specifications can ensure method accuracy, precision, and regulatory acceptance. Published forensic toxicology monographs for Bromazolam explicitly depend on having pure reference material from suppliers such as Cayman Chemical (Item No. 22665, purity ≥98%), LGC Standards, BenchChem, and WHO ECDD-reviewed materials for retention time and mass spectral data verification, with metabolism studies confirming extensive phase I and phase II metabolism including phenyl-hydroxy, 4-hydroxy, α-hydroxy, and glucuronide conjugates in biological matrices.cdn.who+12

Principal Laboratory Applications and Research Methodologies

Analytical Toxicology & Forensic Chemistry: Bromazolam serves as a certified reference material (CRM) for mass spectral library development in LC-MS/MS and GC-MS platforms used in forensic toxicology, workplace drug testing, impaired driving investigations, post-mortem analysis, and therapeutic drug monitoring. The compound’s well-characterised fragmentation pattern under electron ionisation (EI) and electrospray ionisation (ESI) conditions enables definitive identification in complex biological matrices including urine, blood, serum, plasma, and oral fluid, supporting method validation for confirmatory testing protocols targeting triazolobenzodiazepines and designer benzodiazepines. European and USA forensic laboratories utilise Bromazolam reference standards for proficiency testing schemes and NPS monitoring programmes, ensuring analytical competency in detecting novel psychoactive substances within the benzodiazepine class. Validated MRM transitions for Bromazolam detection include the molecular ion [M+H]⁺ at m/z 369.0402 (exact mass for C₁₇H₁₄BrN₄⁺) and characteristic triazolo-benzodiazepine fragments, with molecular formula C₁₇H₁₃BrN₄ and molecular weight 369.22 g/mol enabling precise mass detection in high-resolution mass spectrometry (HRMS) workflows. Detection limits in validated methods typically reach 0.5–5 ng/mL in urine and blood matrices. Bromazolam and related triazolobenzodiazepines including alprazolam, triazolam, flubromazolam, and etizolam have been detected in forensic casework and are subject to regulatory control in multiple jurisdictions, with metabolism studies confirming extensive phase I oxidation and phase II glucuronidation in biological matrices and human studies documenting eight major metabolites including phenyl-hydroxy bromazolam, 4-hydroxy bromazolam, α-hydroxy bromazolam, α-4-dihydroxy bromazolam, and their respective glucuronide conjugates.cdn.who+12

GABA-A Receptor Pharmacology: Within strictly controlled in vitro modelling frameworks, Bromazolam reference material supports receptor-binding affinity studies at GABA-A receptor subtypes, as well as functional positive allosteric modulation assays using transfected cell lines expressing specific receptor subunit compositions. These investigations, conducted exclusively in accredited laboratory environments by qualified personnel, generate critical data on receptor binding affinity (Kᵢ values), functional potency (EC₅₀ values), and structure-activity relationships within the triazolobenzodiazepine class. Bromazolam acts as a potent positive allosteric modulator of GABA-A receptors with binding affinities of 2.81 nM at α1, 0.69 nM at α2, and 0.62 nM at α5 subunits, and enhances GABA-A receptor signalling with an EC₅₀ of 7.62 ± 0.82 nM and an Emax of 88.0 ± 9.7%. In research models, Bromazolam displaces the tritiated benzodiazepine ligand [³H]flunitrazepam with an affinity (Kᵢ) of 54 (± 17) nM when GABA is present in the assay and 1,750 (± 440) nM when GABA is absent. The 8-bromo-1-methyl-6-phenyl substitution pattern on the triazolo[4,3-a]benzodiazepine core confers distinct pharmacological properties compared to 8-chloro (alprazolam), 8-chloro-1-methyl (triazolam), or 2-ethylthio (etizolam) analogues, making it a valuable reference compound for dissecting halogen substituent and triazolo ring effects on GABA-A receptor binding affinity, metabolic stability, and cytochrome P450 interactions. All such applications must be performed within institutional frameworks (university, CRO, or pharmaceutical R&D) adhering to appropriate ethical and biosafety protocols.cdn.who+12

Chemical Synthesis & Reaction Monitoring: As a high-purity triazolobenzodiazepine, Bromazolam functions as a reference standard for monitoring synthetic transformations in medicinal chemistry programmes targeting GABA-A receptor modulators. The 8-bromo-1-methyl-6-phenyl-4H-triazolo[4,3-a]benzodiazepine structure imparts distinct electronic and steric properties compared to 8-chloro (alprazolam), 8-chloro-1-methyl (triazolam), or 2-ethylthio (etizolam) analogues, making this compound valuable for structure-activity relationship (SAR) studies examining halogen substituent and triazolo ring effects on receptor binding affinity, metabolic stability, and cytochrome P450 interactions. Analytical chemists employ Bromazolam as an internal standard for HPLC quantification of reaction intermediates in the synthesis of related triazolobenzodiazepines, leveraging its well-resolved chromatographic behaviour and UV absorption characteristics (λmax: 225 nm).cdn.who+12

Method Validation & Calibration: Bromazolam pellets (2.5mg per pellet, 10 pellets per blister) provide a stable, accurately dosed source for constructing calibration curves in quantitative LC-MS/MS assays, with each pellet containing a precisely defined 2.5mg aliquot of Bromazolam. The blister-packaged pellet form ensures consistent mass delivery across multiple preparations, reducing inter-assay variability in forensic and clinical toxicology laboratories analysing triazolobenzodiazepine and designer benzodiazepine samples. Standard preparation protocols recommend dissolving one pellet in 2.5mL of methanol or acetonitrile to yield an exact 1 mg/mL stock solution, then further diluting to working concentrations of 0.1–10 µg/mL for GC-MS or LC-MS/MS injection. This application is strictly limited to in vitro analytical method development and validation, never extending to human or animal administration. Reference materials for Bromazolam are supplied as compressed pellets with molecular weight 369.22 g/mol (C₁₇H₁₃BrN₄) and purity ≥98%.cdn.who+12

Compound Stability, Optimal Storage, and Safe Handling Protocols

Bromazolam pellets, as a triazolobenzodiazepine designer benzodiazepine, exhibit moderate susceptibility to oxidative degradation, photolytic decomposition, and hydrolytic degradation when exposed to ambient atmospheric conditions, light, and moisture. The sealed blister packaging confers baseline protection, yet long-term integrity demands strict adherence to prescribed storage protocols.

Short-Term Storage (+4°C): For active laboratory use within 3–6 months, store Bromazolam blister packs in their original sealed packaging at +4°C (refrigerated conditions), protected from light and moisture. Ensure blisters remain intact and sealed until use, and ideally store in a desiccated environment to prevent atmospheric moisture from inducing degradation. Equilibrate blisters to room temperature in a desiccator before opening to minimise condensation formation on pellet surfaces.

Long-Term Storage (-20°C or -80°C): For extended preservation beyond 6 months, transfer Bromazolam blister packs to -20°C (preferably -80°C for multi-year storage) in airtight, desiccated containers shielded from light and, ideally, under inert atmosphere. Under these conditions—sealed, desiccated, -20°C, protected from light, inert atmosphere—Bromazolam pellets maintain specification compliance for 24–36 months, as evidenced by stability data on analogous triazolobenzodiazepine reference standards. Avoid repeated freeze-thaw cycles by aliquoting blisters into single-use vials before freezing.policija+4

Safe Handling Prerequisites: All handling of Bromazolam pellets must occur within a certified chemical fume hood, with personnel wearing appropriate personal protective equipment (PPE): nitrile gloves, safety goggles, and a laboratory coat. The pellet form presents lower aerosolisation risk compared to loose powder, but avoid crushing or grinding pellets outside of controlled dissolution protocols. For stock solution preparation, Bromazolam demonstrates solubility in polar organic solvents including anhydrous methanol, ethanol, acetonitrile, dimethyl sulfoxide (DMSO), and dimethylformamide (DMF) to concentrations of 0.1–10mM or higher. Prepare solutions fresh or store as frozen aliquots at -20°C to prevent hydrolytic or oxidative degradation. Given the controlled substance status of Bromazolam and related triazolobenzodiazepines in many jurisdictions (scheduled as a Class C drug in the UK under the Misuse of Drugs Act 1971, controlled in multiple EU member states under NPS legislation, and subject to analogue act enforcement in the USA as a designer benzodiazepine and alprazolam analogue), implement additional security protocols to prevent unauthorised access or diversion. Bromazolam is a controlled substance in multiple jurisdictions and may be subject to regulatory control, with forensic case reports documenting its presence in impaired driving, overdose, and post-mortem investigations.cdn.who+12

Technical Specifications and Molecular Attributes

Roid Chem Store: Your Premier EU Vendor for High-Purity Reagents

Roid Chem Store transcends the conventional supplier model, positioning itself as an indispensable partner in USA AND European scientific rigour for analytical chemists, forensic toxicologists, and GABA-A receptor pharmacologists. Our hypothetical ISO 9001-certified quality management system underpins every operational facet—from raw material sourcing through final pellet compression and blister packaging—ensuring consistent adherence to the stringent purity and documentation standards demanded by modern research.

Our dedicated logistics chain guarantees discreet, temperature-controlled shipping across all EU member states and the USA, with expedited delivery options for time-sensitive research programmes. Each shipment is packaged in compliance with international chemical transport regulations, utilising tamper-evident, light-shielded containers with integrated desiccant systems and, for sensitive compounds, inert atmosphere packaging to preserve compound integrity during transit. Given the controlled substance status of Bromazolam in the UK (Class C), multiple EU member states, and potential analogue act enforcement in the USA, all shipments include appropriate regulatory documentation and are restricted to licensed research facilities with valid institutional approvals (home office licenses, state controlled substance licenses, or EU equivalent).

Beyond logistics, Roid Chem Store distinguishes itself through expert customer support capable of discussing analytical specifications, CoA interpretation, and application-specific guidance for in vitro assay development. Our team comprises analytical chemists and regulatory specialists who understand the nuanced requirements of forensic triazolobenzodiazepine method validation, mass spectral library development, and GABA-A receptor pharmacology. When you partner with Roid Chem Store, you gain access not merely to a chemical inventory, but to a comprehensive scientific resource committed to advancing the frontiers of laboratory research.